ArticleGenome medicine2011
Genetic variants in the MRPS30 region and postmenopausal breast cancer risk.
Article in Genome medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Bioinformatics insights into mitochondrial and immune gene regulation in Alzheimer's disease.European journal of medical research · 2025Article
- Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.Journal of the National Cancer Institute · 2024Article
- Comparative Serum Proteome Profiling of Canine Benign Prostatic Hyperplasia before and after Castration.Animals : an open access journal from MDPI · 2023Article
- Role of mitochondrial translation in remodeling of energy metabolism in ER/PR(+) breast cancer.Frontiers in oncology · 2022Article
- Functional Screenings Identify Regulatory Variants Associated with Breast Cancer Susceptibility.Current issues in molecular biology · 2021Article
- Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population.Frontiers in oncology · 2021Review
- MRPS30-DT Knockdown Inhibits Breast Cancer Progression by Targeting Jab1/Cops5.Frontiers in oncology · 2019Article
- Identifying optimal biomarker combinations for treatment selection through randomized controlled trials.Clinical trials (London, England) · 2015Article
- Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke.Seminars in reproductive medicine · 2014Review
- Replication of breast cancer susceptibility loci in whites and African Americans using a Bayesian approach.American journal of epidemiology · 2014Article
- Gene-environment interactions for breast cancer risk among Chinese women: a report from the Shanghai Breast Cancer Genetics Study.American journal of epidemiology · 2013Article
- Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction.Biometrika · 2012Article
- Simultaneously testing for marginal genetic association and gene-environment interaction.American journal of epidemiology · 2012Article
- Genetic variants in the MRPS30 region and postmenopausal breast cancer risk.Genome medicine · 2012Article
- Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk.Genome medicine · 2012Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGenome-wide association studies have identified several genomic regions that are associated with breast cancer risk, but these provide an explanation for only a small fraction of familial breast cancer aggregation. Genotype by environment interactions may contribute further to such explanation, and may help to refine the genomic regions of interest.
methodsWe examined genotypes for 4,988 SNPs, selected from recent genome-wide studies, and four randomized hormonal and dietary interventions among 2,166 women who developed invasive breast cancer during the intervention phase of the Women's Health Initiative (WHI) clinical trial (1993 to 2005), and one-to-one matched controls. These SNPs derive from 3,224 genomic regions having pairwise squared correlation (r2) between adjacent regions less than 0.2. Breast cancer and SNP associations were identified using a test statistic that combined evidence of overall association with evidence for SNPs by intervention interaction.
resultsThe combined 'main effect' and interaction test led to a focus on two genomic regions, the fibroblast growth factor receptor two (FGFR2) and the mitochondrial ribosomal protein S30 (MRPS30) regions. The ranking of SNPs by significance level, based on this combined test, was rather different from that based on the main effect alone, and drew attention to the vicinities of rs3750817 in FGFR2 and rs7705343 in MRPS30. Specifically, rs7705343 was included with several FGFR2 SNPs in a group of SNPs having an estimated false discovery rate < 0.05. In further analyses, there were suggestions (nominal P < 0.05) that hormonal and dietary intervention hazard ratios varied with the number of minor alleles of rs7705343.
conclusionsGenotype by environment interaction information may help to define genomic regions relevant to disease risk. Combined main effect and intervention interaction analyses raise novel hypotheses concerning the MRPS30 genomic region and the effects of hormonal and dietary exposures on postmenopausal breast cancer risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.